Compare NN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NN | ZLAB |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2021 | 2017 |
| Metric | NN | ZLAB |
|---|---|---|
| Price | $11.48 | $24.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $33.67 | $33.14 |
| AVG Volume (30 Days) | ★ 2.5M | 743.1K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | $4,573,000.00 | ★ $460,156,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $10.77 | $15.96 |
| 52 Week High | $24.42 | $31.85 |
| Indicator | NN | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 27.37 | 46.31 |
| Support Level | N/A | $24.81 |
| Resistance Level | $17.65 | $25.28 |
| Average True Range (ATR) | 0.99 | 0.94 |
| MACD | -0.25 | -0.16 |
| Stochastic Oscillator | 10.75 | 32.84 |
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system delivers resilient, next-generation, complementary positioning, navigation, and timing (PNT) solutions designed to overcome the limitations and vulnerabilities of existing space-based Global Navigation Satellite Systems (GNSS), including the Global Positioning System (GPS). The products of the company include NextNav Pinnacle: Accurate vertical location, NextNav 3D: 3D location visualization, NextNav TerraPoiNT: Resilient PNT for 3D and indoor geolocation, Next Generation Solution: Terrestrial 3D PNT powered by spectrum.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.